In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.

HOUSTON -- Two-thirds of patients with PI3K -mutant brain metastases responded to the maximum tolerated dose (MTD) of the ...

Data accumulated to date with respect to various PI3K inhibitors suggest improved response rates and longer survival compared with existing therapeutic options. Longer-term follow-up is essential ...